What is Xtant Medical Holdings, Inc. (XTNT)'s fair-value range?

As of 2026-09-03, Xtant Medical Holdings, Inc. (XTNT) trades at $0.41 — Cboe · delayed 15 min · as of 03:42 ET. That price implies EV/EBITDA 3.7×. Whether those assumptions are reasonable is your call: every method on the page shows the number today's price implies for its key input — the P/E, the growth rate, the multiple — and you set your own, from a 1, 3, 5 or 10-year filed CAGR or a rate of your choosing. With EvidInvest's preset inputs the 3 methods land at $0.50–$0.84; presets are filed history and reference settings, not a recommendation. Not investment advice.

How is Xtant Medical Holdings, Inc. (XTNT)'s fair value calculated?

Xtant Medical Holdings, Inc. (XTNT)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples (PE, EV/EBITDA, P/S, P/B) benchmarked against its industry — using data from SEC filings.

What is Xtant Medical Holdings, Inc. (XTNT)'s PE ratio versus its industry?

EvidInvest shows Xtant Medical Holdings, Inc. (XTNT)'s current and historical PE ratio alongside its sector and industry averages, so you can see whether the stock trades at a premium or discount to peers. Full breakdown at https://evidinvest.com/valuation/XTNT.

Fair value · Xtant Medical Holdings, Inc. (XTNT) · updated 2026-09-03 · from 10-K FY2025

Xtant Medical Holdings trades at $0.41. That price implies 3.7× EV/EBITDA.

Cboe · delayed 15 min · as of 03:42 ET

Are those assumptions reasonable? Use XTNT’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

EV/EBITDA: 3.7×

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings. This price: Cboe · delayed 15 min · as of 03:42 ET.

With preset inputs the methods land at $0.50 – $0.84 (presets are filed history and our reference settings, not a recommendation)

Price $0.41

Bear $0.50Base $0.56Bull $0.84

Set your own assumptions ↓See how each method got its number Check another stock

How each method got its number

Bear, base and bull are the 25th, 50th and 75th percentile of the methods that produced a usable estimate. Weights say how much a method is trusted for this sector; they do not change the range.

Method	Estimate	vs price	Weight	Why this method
DCF High weight Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions.	$0.43	+5%	High weight	Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions.
Earnings Power Value Medium weight Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth.	$0.56	+37%	Medium weight	Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth.
EV/EBITDA Medium weight Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it.	$1.13	+176%	Medium weight	Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it.
P/E vs sector Medium weight Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. Negative or unavailable EPS	No estimate		Medium weight	Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer.
Growth-trajectory DCF Medium weight A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. No trajectory data available	No estimate		Medium weight	A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate.
P/B vs sector Medium weight Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. P/B comparable is optional for non-financial companies	No estimate		Medium weight	Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software.
Graham Number Medium weight Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. Requires positive EPS	No estimate		Medium weight	Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech.
EV/FCF Medium weight 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. Negative FCF — common for growth companies; ratio not meaningful	No estimate		Medium weight	20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing.

What this means

The methods differ by about 68%, from $0.50 to $0.84. That is normal: cash-flow methods and peer multiples see different things. Use the range, not a single number.
The base case, $0.56, is the median of the 3 methods with data. It assumes Xtant Medical Holdings’s current margins, cash generation and share count persist; it does not price in a new product cycle, a recession or a buyback surge.
The number moves when the filings move. The next 10-Q replaces the oldest quarter in the trailing-twelve-month EPS and cash-flow inputs; the last one (Q2 FY2026) was filed 2026-08-11. The price changes every day; the fair value only changes with the filings.

The filing behind these numbers

Xtant Medical Holdings, Inc.

Revenue: $133.9M
Diluted EPS: $0.03
Free cash flow: $10.2M; operating cash flow − capital expenditure
Diluted shares: 150.0M; weighted average

10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-31 · accession 0001493152-26-013792

Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q2 FY2026 (filed 2026-08-11).

Open this filing on sec.gov

Xtant Medical Holdings trades at $0.41. That price implies 3.7× EV/EBITDA.

Cboe · delayed 15 min · as of 03:42 ET

Are those assumptions reasonable? Use XTNT’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

EV/EBITDA: 3.7×

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings. This price: Cboe · delayed 15 min · as of 03:42 ET.

With preset inputs the methods land at $0.50 – $0.84 (presets are filed history and our reference settings, not a recommendation)

Price $0.41

Bear $0.50Base $0.56Bull $0.84

How each method got its number

Bear, base and bull are the 25th, 50th and 75th percentile of the methods that produced a usable estimate. Weights say how much a method is trusted for this sector; they do not change the range.

Method	Estimate	vs price	Weight	Why this method
DCF High weight Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions.	$0.43	+5%	High weight	Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions.
Earnings Power Value Medium weight Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth.	$0.56	+37%	Medium weight	Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth.
EV/EBITDA Medium weight Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it.	$1.13	+176%	Medium weight	Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it.
P/E vs sector Medium weight Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. Negative or unavailable EPS	No estimate		Medium weight	Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer.
Growth-trajectory DCF Medium weight A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. No trajectory data available	No estimate		Medium weight	A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate.
P/B vs sector Medium weight Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. P/B comparable is optional for non-financial companies	No estimate		Medium weight	Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software.
Graham Number Medium weight Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. Requires positive EPS	No estimate		Medium weight	Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech.
EV/FCF Medium weight 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. Negative FCF — common for growth companies; ratio not meaningful	No estimate		Medium weight	20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing.

What this means

The methods differ by about 68%, from $0.50 to $0.84. That is normal: cash-flow methods and peer multiples see different things. Use the range, not a single number.

The base case, $0.56, is the median of the 3 methods with data. It assumes Xtant Medical Holdings’s current margins, cash generation and share count persist; it does not price in a new product cycle, a recession or a buyback surge.

The number moves when the filings move. The next 10-Q replaces the oldest quarter in the trailing-twelve-month EPS and cash-flow inputs; the last one (Q2 FY2026) was filed 2026-08-11. The price changes every day; the fair value only changes with the filings.

Year	Stage	FCF	Present value
1	Stage 1	$9M	$8M
2	Stage 1	$8M	$6M
3	Stage 1	$7M	$5M
4	Stage 1	$6M	$4M
5	Stage 1	$6M	$3M
6	Stage 2	$6M	$3M
7	Stage 2	$6M	$3M
8	Stage 2	$6M	$2M
9	Stage 2	$6M	$2M
10	Stage 2	$6M	$2M

Year

Stage

FCF

Present value

Stage 1

$9M

$8M

Stage 1

$8M

$6M

Stage 1

$7M

$5M

Stage 1

$6M

$4M

Stage 1

$6M

$3M

Stage 2

$6M

$3M

Stage 2

$6M

$3M

Stage 2

$6M

$2M

Stage 2

$6M

$2M

Stage 2

$6M

$2M

Year	Stage	FCF	Present value
1	Stage 1	$9M	$8M
2	Stage 1	$8M	$6M
3	Stage 1	$7M	$5M
4	Stage 1	$6M	$4M
5	Stage 1	$6M	$3M
6	Stage 2	$6M	$3M
7	Stage 2	$6M	$3M
8	Stage 2	$6M	$2M
9	Stage 2	$6M	$2M
10	Stage 2	$6M	$2M

Year

Stage

FCF

Present value

Stage 1

$9M

$8M

Stage 1

$8M

$6M

Stage 1

$7M

$5M

Stage 1

$6M

$4M

Stage 1

$6M

$3M

Stage 2

$6M

$3M

Stage 2

$6M

$3M

Stage 2

$6M

$2M

Stage 2

$6M

$2M

Stage 2

$6M

$2M

Xtant Medical Holdings trades at $0.41. That price implies 3.7× EV/EBITDA.

How each method got its number

What this means

The filing behind these numbers

Xtant Medical Holdings trades at $0.41. That price implies 3.7× EV/EBITDA.

How each method got its number

What this means

The filing behind these numbers

Valuation tool: build your own XTNT range

Daily Price — XTNT

Range implied by today’s price3 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on XTNT

Compare with peers

Explore

Valuation tool: build your own XTNT range

Daily Price — XTNT

Range implied by today’s price3 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on XTNT

Compare with peers

Explore